Doctors conducted a first-in-human study to see if a new treatment called VS-01 is safe for people with advanced liver disease. The study included 12 patients who had liver cirrhosis with fluid buildup and mild brain changes related to their liver condition. All patients received the VS-01 infusion directly into their abdomen, with some receiving a single dose and others receiving multiple doses over four days.
The main goal was to check for side effects. Researchers found that VS-01 was generally well-tolerated. Out of 12 patients, 7 experienced a total of 20 side effects, but most were mild and short-lived. No serious side effects were reported, and no one had to stop the treatment because of side effects. The most common issues were related to the stomach and intestines.
It is very important to understand what this study does and does not tell us. This was a very early, phase 1b study with only 12 people and no comparison group. It was not designed to see if VS-01 helps treat liver disease—it only checked if it was safe in the short term. The follow-up period was just 7 days after the last dose.
Readers should know this is a first step in a long research process. The results are cautiously positive for safety in this small group, but much larger and longer studies are needed to confirm these findings and to learn if VS-01 is actually effective for patients.